{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T07:43:18Z","timestamp":1788507798980,"version":"build-2803163510"},"reference-count":40,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.clgc.2019.05.002","type":"journal-article","created":{"date-parts":[[2019,5,13]],"date-time":"2019-05-13T11:01:21Z","timestamp":1557745281000},"page":"291-298","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Cabozantinib in Renal Cell Carcinoma With Brain Metastases: Safety and Efficacy in a Real-World Population"],"prefix":"10.1016","volume":"17","author":[{"given":"Giorgia","family":"Peverelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Raimondi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Ratta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Verzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Bregni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Cortesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Carten\u00ec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Fornarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7430-001X","authenticated-orcid":false,"given":"Gaetano","family":"Facchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0876-0226","authenticated-orcid":false,"given":"Sebastiano","family":"Buti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Galli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Tucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Prisciandaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Procopio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2019.05.002_bib1","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/S0140-6736(15)00046-X","article-title":"Renal cancer","volume":"387","author":"Capitanio","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.clgc.2019.05.002_bib2","first-page":"7","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clgc.2019.05.002_bib3","author":"Ferlay"},{"key":"10.1016\/j.clgc.2019.05.002_bib4","doi-asserted-by":"crossref","first-page":"15","DOI":"10.5301\/tj.5000581","article-title":"Treatment of advanced renal cell carcinoma: recent advances and current role of immunotherapy, surgery, and cryotherapy","volume":"103","author":"Mennitto","year":"2016","journal-title":"Tumori J"},{"key":"10.1016\/j.clgc.2019.05.002_bib5","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon-alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2019.05.002_bib6","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2019.05.002_bib7","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1303989","article-title":"Pazopanib versus sunitinib in metastatic renal-cell carcinoma","volume":"369","author":"Motzer","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2019.05.002_bib8","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/S0140-6736(11)61613-9","article-title":"Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial","volume":"378","author":"Rini","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.clgc.2019.05.002_bib9","doi-asserted-by":"crossref","first-page":"3791","DOI":"10.1200\/JCO.2012.47.4940","article-title":"Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial","volume":"31","author":"Motzer","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2019.05.002_bib10","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.2147\/DDDT.S104225","article-title":"Cabozantinib in the treatment of advanced renal cell carcinoma: design, development, and potential place in the therapy","volume":"10","author":"Grassi","year":"2016","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.clgc.2019.05.002_bib11","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1056\/NEJMoa1510016","article-title":"Cabozantinib versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Choueiri","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2019.05.002_bib12","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S1470-2045(16)30107-3","article-title":"Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial","volume":"17","author":"Choueiri","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2019.05.002_bib13","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1200\/JCO.2016.70.7398","article-title":"Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the Alliance A031203 CABOSUN trial","volume":"35","author":"Choueiri","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2019.05.002_bib14","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.neuchi.2013.12.001","article-title":"Brain metastasis from renal cell carcinoma","volume":"60","author":"Bennani","year":"2014","journal-title":"Neurochirurgie"},{"key":"10.1016\/j.clgc.2019.05.002_bib15","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.clgc.2013.04.012","article-title":"Prognostic factors of survival for patients with metastatic renal cell carcinoma with brain metastases treated with targeted therapy: results from the International Metastatic Renal Cell Carcinoma Database Consortium","volume":"11","author":"Vickers","year":"2013","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2019.05.002_bib16","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.clgc.2017.05.010","article-title":"Prognostic factors for survival of patients with synchronous or metachronous brain metastasis of renal cell carcinoma","volume":"15","author":"Choi","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2019.05.002_bib17","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1093\/neuonc\/noy099","article-title":"Estimating survival for renal cell carcinoma patients with brain metastases: an update of the Renal Graded Prognostic Assessment tool","volume":"20","author":"Sperduto","year":"2018","journal-title":"Neuro Onco"},{"key":"10.1016\/j.clgc.2019.05.002_bib18","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1002\/(SICI)1097-0142(19981215)83:12<2548::AID-CNCR21>3.0.CO;2-4","article-title":"Prognostic factors for survival in patients with brain metastases from renal cell carcinoma","volume":"83","author":"Culine","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2019.05.002_bib19","doi-asserted-by":"crossref","first-page":"e735","DOI":"10.1016\/j.clgc.2018.01.016","article-title":"Exposure to multiple lines of treatment and survival of patients with metastatic renal cell carcinoma: a real-world analysis","volume":"16","author":"Ratta","year":"2018","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2019.05.002_bib20","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/j.1464-410X.2010.09895.x","article-title":"Simultaneous anti-angiogenic therapy and single-fraction radiosurgery in clinically relevant metastases from renal cell carcinoma","volume":"108","author":"Staehler","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.clgc.2019.05.002_bib21","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.clgc.2012.11.001","article-title":"Brain metastases from renal cell carcinoma in the era of tyrosine kinase inhibitors","volume":"11","author":"Dudek","year":"2013","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2019.05.002_bib22","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S1470-2045(09)70162-7","article-title":"Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial","volume":"10","author":"Gore","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2019.05.002_bib23","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/bjc.2015.196","article-title":"Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma","volume":"113","author":"Gore","year":"2015","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clgc.2019.05.002_bib24","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1002\/cncr.25452","article-title":"Sunitinib in metastatic renal cell carcinoma patients with brain metastases","volume":"117","author":"Gore","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2019.05.002_bib25","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1002\/cncr.24864","article-title":"Safety and efficacy results of the advanced renal cell carcinoma sorafenib Expanded Access Program in North America","volume":"116","author":"Stadler","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2019.05.002_bib26","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1093\/annonc\/mdq651","article-title":"Final results of the European advanced renal cell carcinoma sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings","volume":"22","author":"Beck","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2019.05.002_bib27","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jtho.2016.09.127","article-title":"Intracranial activity of cabozantinib in MET exon 14\u2013positive NSCLC with brain metastases","volume":"12","author":"Klempner","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.clgc.2019.05.002_bib28","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1186\/s13256-018-1875-9","article-title":"Activity of cabozantinib in radioresistant brain metastases from renal cell carcinoma: two case reports","volume":"25","author":"N\u00e9grier","year":"2018","journal-title":"J\u00a0Med Case Rep"},{"issue":"15 suppl","key":"10.1016\/j.clgc.2019.05.002_bib29","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1200\/JCO.2017.35.15_suppl.4569","article-title":"Inter and intra-tumor heterogeneity of PD-L1 and MET expression in metastatic renal cell carcinoma (mRCC)","volume":"35","author":"Derosa","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2019.05.002_bib30","unstructured":"De Liano AG, Venugopal B, Fife K, et\u00a0al. Cabozantinib in metastatic renal cell carcinoma (mRCC): Real world experience from the UK. J Clin Oncol 36 (15 suppl)."},{"key":"10.1016\/j.clgc.2019.05.002_bib31","doi-asserted-by":"crossref","first-page":"e1069","DOI":"10.1016\/j.clgc.2018.06.005","article-title":"Exceptional response to cabozantinib of rapidly evolving brain metastases of renal cell carcinoma: a case report and review of the literature","volume":"16","author":"Ciccarese","year":"2018","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2019.05.002_bib32","first-page":"1","article-title":"Overall survival and response to radiation and targeted therapies among patients with renal cell carcinoma brain metastases","volume":"18","author":"Juloori","year":"2019","journal-title":"J\u00a0Neurosurg"},{"key":"10.1016\/j.clgc.2019.05.002_bib33","first-page":"217","article-title":"Multimodality treatment of brain metastasis from renal cell carcinoma in the era of targeted therapy","volume":"9","author":"Bassanelli","year":"2017","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.clgc.2019.05.002_bib34","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.clgc.2014.06.002","article-title":"Safety and efficacy of targeted therapy for renal cell carcinoma with brain metastasis","volume":"13","author":"Bastos","year":"2015","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2019.05.002_bib35","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1093\/annonc\/mdx408","article-title":"Combined irradiation and targeted therapy or immune checkpoint blockade in brain metastases: toxicities and efficacy","volume":"28","author":"Tallet","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2019.05.002_bib36","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/CAD.0000000000000349","article-title":"Safety assessment of molecular targeted therapies in association with radiotherapy in metastatic renal cell carcinoma: a real-life report","volume":"27","author":"Langrand-Escure","year":"2016","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.clgc.2019.05.002_bib37","doi-asserted-by":"crossref","first-page":"e945","DOI":"10.1016\/j.clgc.2018.03.014","article-title":"Safety and efficacy of cabozantinib in metastatic renal-cell carcinoma: real-world data from an Italian Managed Access Program","volume":"16","author":"Procopio","year":"2018","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2019.05.002_bib39","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2019.05.002_bib40","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.clgc.2013.09.008","article-title":"A\u00a0phase II trial of sunitinib in patients with renal cell cancer and untreated brain metastases","volume":"12","author":"Chevreau","year":"2014","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2019.05.002_bib41","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s11060-016-2238-2","article-title":"Impact of resection and systemic therapy on the survival of patients with brain metastasis of metastatic renal cell carcinoma","volume":"130","author":"Du","year":"2016","journal-title":"J\u00a0Neuro Oncol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767318306529?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767318306529?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:31:31Z","timestamp":1761564691000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767318306529"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S1558767318306529"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2019.05.002","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cabozantinib in Renal Cell Carcinoma With Brain Metastases: Safety and Efficacy in a Real-World Population","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2019.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}